HomeCompareKNTE vs EPRT

KNTE vs EPRT: Dividend Comparison 2026

KNTE yields 75.47% · EPRT yields 3.97%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 KNTE wins by $1.29M in total portfolio value
10 years
KNTE
KNTE
● Live price
75.47%
Share price
$2.65
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.35M
Annual income
$375,142.22
Full KNTE calculator →
EPRT
EPRT
● Live price
3.97%
Share price
$30.36
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$64.3K
Annual income
$13,170.85
Full EPRT calculator →

Portfolio growth — KNTE vs EPRT

📍 KNTE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodKNTEEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, KNTE + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
KNTE pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KNTE
Annual income on $10K today (after 15% tax)
$6,415.09/yr
After 10yr DRIP, annual income (after tax)
$318,870.89/yr
EPRT
Annual income on $10K today (after 15% tax)
$337.37/yr
After 10yr DRIP, annual income (after tax)
$11,195.22/yr
At 15% tax rate, KNTE beats the other by $307,675.66/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KNTE + EPRT for your $10,000?

KNTE: 50%EPRT: 50%
100% EPRT50/50100% KNTE
Portfolio after 10yr
$708.6K
Annual income
$194,156.54/yr
Blended yield
27.40%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

KNTE
Analyst Ratings
2
Buy
4
Hold
Consensus: Hold
Price Target
$30.00
+1032.1% upside vs current
Range: $30.00 — $30.00
Altman Z
1.0
Piotroski
2/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+16.9% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KNTE buys
0
EPRT buys
0
No recent congressional trades found for KNTE or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricKNTEEPRT
Forward yield75.47%3.97%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$1.35M$64.3K
Annual income after 10y$375,142.22$13,170.85
Total dividends collected$1.17M$38.7K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldBuy
Analyst price target$30.00$35.50

Year-by-year: KNTE vs EPRT ($10,000, DRIP)

YearKNTE PortfolioKNTE Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$18,247$7,547.17$11,212$512.01+$7.0KKNTE
2$32,395$12,870.51$12,689$692.09+$19.7KKNTE
3$56,017$21,354.74$14,521$944.30+$41.5KKNTE
4$94,449$34,510.84$16,841$1,302.88+$77.6KKNTE
5$155,442$54,381.15$19,841$1,821.64+$135.6KKNTE
6$249,967$83,643.80$23,818$2,587.47+$226.1KKNTE
7$393,173$125,708.24$29,230$3,744.65+$363.9KKNTE
8$605,486$184,791.09$36,816$5,540.38+$568.7KKNTE
9$913,831$265,960.98$47,806$8,413.17+$866.0KKNTE
10$1,352,941$375,142.22$64,324$13,170.85+$1.29MKNTE

KNTE vs EPRT: Complete Analysis 2026

KNTEStock

Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.

Full KNTE Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this KNTE vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KNTE vs SCHDKNTE vs JEPIKNTE vs OKNTE vs KOKNTE vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.